Yap, Yoon-Sim <br/><br/>
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.  [electronic resource] 

 -  JAMA oncology  Nov 2017 
 - 1538-1545 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>2374-2445 
<br/><br/><label>Standard No.: </label>10.1001/jamaoncol.2017.1269  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antimetabolites, Antineoplastic--adverse effects<br/>Asian People--genetics<br/>Capecitabine--adverse effects<br/>Chi-Square Distribution<br/>Dihydrouracil Dehydrogenase (NADP)--genetics<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Folic Acid--blood<br/>Genetic Predisposition to Disease<br/>Genome-Wide Association Study<br/>Hand-Foot Syndrome--blood<br/>Humans<br/>Incidence<br/>Intracellular Signaling Peptides and Proteins--genetics<br/>Kaplan-Meier Estimate<br/>Logistic Models<br/>Male<br/>Membrane Proteins--genetics<br/>Microfilament Proteins--genetics<br/>Middle Aged<br/>Multivariate Analysis<br/>Neoplasms--blood<br/>Odds Ratio<br/>Pharmacogenomic Variants<br/>Polymorphism, Single Nucleotide<br/>Predictive Value of Tests<br/>Pyridoxine--administration & dosage<br/>Risk Assessment<br/>Risk Factors<br/>Severity of Illness Index<br/>Singapore--epidemiology<br/>Time Factors<br/>Treatment Outcome